PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
22.24%
ROE 20-25% – Strong performance. Benjamin Graham might check if leverage artificially boosts ROE. Examine Debt-to-Equity.
-98.77%
Negative ROA indicates net losses or excessive assets. Benjamin Graham would question viability or capital misallocation.
-160.89%
Negative ROCE suggests negative EBIT or an inflated capital base. Benjamin Graham would check if the firm is structurally unprofitable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.